1995
General Cognitive Ability Following Unilateral and Bilateral Fetal Ventral Mesencephalic Tissue Transplantation for Treatment of Parkinson's Disease
Sass K, Buchanan C, Westerveld M, Marek K, Farhi A, Robbins R, Naftolin F, Vollmer T, Leranth C, Roth R, Price L, Bunney B, Elsworth J, Hoffer P, Redmond D, Spencer D. General Cognitive Ability Following Unilateral and Bilateral Fetal Ventral Mesencephalic Tissue Transplantation for Treatment of Parkinson's Disease. JAMA Neurology 1995, 52: 680-686. PMID: 7619024, DOI: 10.1001/archneur.1995.00540310050016.Peer-Reviewed Original ResearchConceptsCognitive abilitiesNonverbal cognitive abilityVerbal cognitive abilityInformation-processing speedVerbal memoryNeuropsychological profileTest batteryCognitive functionNormal cognitive functionCognitive dysfunctionRight caudate nucleusCaudate nucleusFactor analysisTissue transplantationParkinson's disease
1992
Unilateral Transplantation of Human Fetal Mesencephalic Tissue into the Caudate Nucleus of Patients with Parkinson's Disease
Spencer D, Robbins R, Naftolin F, Marek K, Vollmer T, Leranth C, Roth R, Price L, Gjedde A, Bunney B, Sass K, Elsworth J, Kier E, Makuch R, Hoffer P, Redmond D. Unilateral Transplantation of Human Fetal Mesencephalic Tissue into the Caudate Nucleus of Patients with Parkinson's Disease. New England Journal Of Medicine 1992, 327: 1541-1548. PMID: 1435880, DOI: 10.1056/nejm199211263272201.Peer-Reviewed Original ResearchMeSH KeywordsActivities of Daily LivingAdultAntiparkinson AgentsCaudate NucleusCryopreservationCyclosporineDopamineFemaleFetal Tissue TransplantationHomovanillic AcidHumansMagnetic Resonance ImagingMaleMesencephalonMiddle AgedMotor ActivityParkinson DiseasePutamenStereotaxic TechniquesTomography, Emission-ComputedConceptsCase patientsParkinson's diseaseMesencephalic tissueCaudate nucleusHuman fetal ventral mesencephalic tissueFetal ventral mesencephalic tissueHuman fetal mesencephalic tissueContinued disease progressionFetal dopaminergic neuronsFetal mesencephalic tissueVentral mesencephalic tissueSevere Parkinson's diseaseOptimal drug therapySigns of parkinsonismMidbrain dopamine neuronsPositron emission tomographyMonths of evaluationAntiparkinsonian medicationUnilateral transplantationDrug holidayMore medicationsStriatonigral degenerationNeurologic functionDopaminergic neuronsDrug therapy
1988
Biochemical analysis of caudate nucleus biopsy samples from parkinsonian patients
Goldstein M, Lieberman A, Helmer E, Koslow M, Ransohoff J, Elsworth J, Roth R, Deutch A. Biochemical analysis of caudate nucleus biopsy samples from parkinsonian patients. Annals Of Neurology 1988, 24: 685-688. PMID: 2904793, DOI: 10.1002/ana.410240517.Peer-Reviewed Original ResearchConceptsBiopsy samplesAdrenal transplantationDopamine functionAutologous adrenal transplantationMetabolite homovanillic acidEnzyme tyrosine hydroxylaseConcentration of dopamineParkinsonian patientsTherapeutic responseHomovanillic acidParkinson's diseaseTyrosine hydroxylasePostmortem valuesBiochemical analysisBiochemical parametersPatientsTransplantationPostmortem changesDisease
1982
The contribution of amphetamine metabolites of (−)-deprenyl to its antiparkinsonian properties
Elsworth J, Sandler M, Lees A, Ward C, Stern G. The contribution of amphetamine metabolites of (−)-deprenyl to its antiparkinsonian properties. Journal Of Neural Transmission 1982, 54: 105-110. PMID: 6809891, DOI: 10.1007/bf01249283.Peer-Reviewed Original Research
1978
Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ‘cheese effect’
Elsworth J, Glover V, Reynolds G, Sandler M, Lees A, Phuapradit P, Shaw K, Stern G, Kumar P. Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ‘cheese effect’. Psychopharmacology 1978, 57: 33-38. PMID: 96466, DOI: 10.1007/bf00426954.Peer-Reviewed Original ResearchConceptsMonoamine oxidase B inhibitorsSelective monoamine oxidase B inhibitorNormal dietCheese effectB inhibitorHuman intestinal mucosaNormal human intestinal mucosaPressor responseOral tyraminePressor reactionDeprenyl administrationAdverse reactionsMonoamine oxidase AIntestinal mucosaOxidase AHuman plateletsPlatelet enzymeDeprenylComplete inhibitionVolunteersDietTyramineInhibitorsMucosaAdministration
1977
DEPRENYL IN PARKINSON'S DISEASE
Lees A, Kohout L, Shaw K, Stern G, Elsworth J, Sandler M, Youdim M. DEPRENYL IN PARKINSON'S DISEASE. The Lancet 1977, 310: 791-795. PMID: 71602, DOI: 10.1016/s0140-6736(77)90725-5.Peer-Reviewed Original ResearchConceptsParkinson's diseaseDouble-blind crossover trialDoses of levodopaEarly morning akinesiaPeripheral decarboxylase inhibitorLevodopa-induced dyskinesiaTotal daily dosesMajority of patientsIdiopathic Parkinson's diseaseDose akinesiaUntreated patientsCrossover trialDosage reductionDaily dosesDecarboxylase inhibitorTherapeutic effectCheese effectLarge dosesPatientsLevodopaAlternate daysAkinesiaDeprenylDiseaseB inhibitor